Corbus's 15min chart sees Bollinger Bands expanding upward and downward.

Corbus's 15-minute chart has triggered both Bollinger Bands Expanding Upward and Bollinger Bands Expanding Downward as of 09/30/2025 at 15:15. This indicates that the market trend is currently being driven by buyer activity, while simultaneously being driven by seller activity.

Corbus Pharmaceuticals (NASDAQ:CRBP) has seen a significant adjustment in its stock price target by Oppenheimer, which lowered its estimate to $53.00 from $60.00 Oppenheimer lowers Corbus Pharmaceuticals stock price target ahead of ESMO data^[1]. The stock, currently trading at $12.26, is well below the analyst consensus range of $28-$55. This move comes as Corbus prepares to present results from approximately 100 additional patients treated with its Nectin-4 targeting ADC, CRB-701, at the upcoming European Society for Medical Oncology (ESMO) conference in October 2025.

The ESMO presentation, scheduled for October 19, 2025, will focus on head and neck squamous cell carcinoma (HNSCC) and cervical cancer patients, comprising about 80 of the study participants. Safety metrics, such as rates of peripheral neuropathy, rash, and ocular events, are expected to be highlighted, as these could differentiate CRB-701 from other Nectin-4 targeting ADCs in development.

Despite the price target reduction, Oppenheimer remains optimistic about CRB-701's potential to demonstrate a differentiated profile. The upcoming ESMO presentation represents an important opportunity to strengthen both safety and efficacy datasets beyond the relatively small numbers reported to date.

In other recent news, Corbus Pharmaceuticals has received an FDA Fast Track Designation for CRB-701, a Nectin-4-targeting antibody-drug conjugate intended for treating recurrent or metastatic head and neck squamous cell carcinoma. Additionally, Corbus will present updated clinical data from its Phase 1/2 study of CRB-701 at the European Society for Medical Oncology Congress in October 2025, covering results from trials involving patients with urothelial and non-urothelial solid tumors. Corbus has also initiated the multiple ascending dose portion of its Phase 1 trial for CRB-913, aimed at treating obesity, following the completion of the single ascending dose portion earlier this year.

Market trends for Corbus's stock have been volatile, with Bollinger Bands expanding both upward and downward as of 09/30/2025 at 15:15, indicating a market driven by both buyer and seller activity.